Bioventus Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-58.9% vs price
Base Case (Median)
1.4% vs price
Bull Case (75th pct.)
54.8% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-8.79 | -159.8% | High (40%) |
| PE Comparable | $17.14 | 16.8% | Medium (25%) |
| Growth Trajectory DCF | $43.61 | 197.1% | Medium (20%) |
| Graham Number | $6.92 | -52.9% | Medium (40%) |
| EV/EBITDA | $14.89 | 1.4% | Medium (20%) |
| EV/FCF | $28.30 | 92.8% | Medium (20%) |
| Earnings Power Value | $5.13 | -65.0% | Medium (50%) |
Based on 7 out of 8 methods, BVS appears fairly valued at the current price of $14.68. The base case fair value of $14.89 implies 1.4% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.